Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 oral cancer and precancer with special reference to verrucous carcinomas

Journal of Oral Pathology and Medicine

Volumn 28, Issue 5, 1999, Pages 226-232

  Saito, Tadashi ^a   Nakajima, Takashi ^a   Mogi, Kenji ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Ki 67; Oral carcinogenesis; P16; P27; P53; PRb; Verrucous carcinoma

Indexed keywords

EID: 0033134697     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.1999.tb02029.x     Document Type: Article

References (51)

1. PARKIN DM, LAARA E, MUIR CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancel 1988; 41: 184-97.
2. BLOT WJ, MCLAUGHLIN JK, WINN DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancel Res 1988; 48: 3282-7.
3. BOFFETTA P, MASHBERG A, WINKELMANN R, GARFINKEL L. Carcinogenic effect of tobacco smoking and alcohol drinking on anatomic sites of the oral cavity and oropharynx. Int J Cancer 1992; 52: 530-3.
4. MASHBERG A, BOFFETTA P, WINKELMAN R, GARFINKEL L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer 1993; 72: 1369-75.
5. KO YC, HUANG YL, LEE CH, CHEN MJ, LIN LM, TSAI CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995; 24: 450-3.
6. REICHART PA. Oral cancer and precancer related to betel and miang chewing in Thailand: a review. J Oral Pathol Med 1995; 24: 241-3.
7. EMILION G, LANGDON JD, SPEIGHT P, PARTRIDGE M. Frequent gene deletions in potentially malignant oral lesions. Br J Cancer 1996; 73: 809-13.
8. MATSUDA H, KONISHI N, HIASA Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996; 25: 232-8.
9. KASHIWAZAKI H, TONOKI H, TADA M, et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogens 1997; 15: 2667-74.
10. SILVERMAN S, GORSKY M, LOZADA F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984; 53: 563-8.
11. KRAUS FT, PEREZMESA C. Verrucous carcinoma. Clinical and pathologic study of 105 cases involving the oral cavity, larynx, and genitalia. Cancer 1966; 19: 26-38.
12. ACKERMAN LV. Verrucous carcinoma of the oral cavity. Surgery 1948; 23: 670-8.
13. GRINSPAN D, ABULAFIA J. Oral florid papillomatosis (verrucous carcinoma). Int J Dermatol 1979; 18: 608-22.
14. SHEAR M, PINDBORG JJ. Verrucous hy perplasia of the oral mucosa. Cancer 1980; 46: 1855-62.
15. SLOOTWEG PJ, MULLER H. Verrucous hyperplasia or verrucous carcinoma. An analysis of 27 patients. J Maxillofac Surg 1983; 11: 13-9.
16. ITOIZ ME, CONTI CJ, LANFRANCHI HE, MAMRACK M, KLEIN SZANTO AJ. Immunohistochemical detection of filaggrin in preneoplastic and neoplastic lesions of the human oral mucosa. Am J Pathol 1985; 119: 456-61.
17. EPIVATIANOS A. Argyrophilic nucleolar organizer region associated proteins in human oral normal mucosa, verrucous carcinoma, and squamous cell carcinoma. Ann Dent 1995; 54: 25-9.
18. DRACHENBERG CB, BLANCHAERT R, IOFFE OB, ORD RA, PAPADIMITRIOU JC. Comparative study of invasive squamous cell carcinoma and verrucous carcinoma of the oral cavity: expression of bcl-2, p53, and Her-2/neu, and indexes of cell turnover. Cancer Detect Prev 1997; 21: 483-9.
19. TAKITA J, HAYASHI Y, NAKAJIMA T, et al. The p16(CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 1998; 17: 3137-43.
20. SANO T, OYAMA T, KASHIWABARA K, FUKUDA T, NAKAJIMA T. Expression status of p16 protein is associated with human papillomavirus oncogene potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8.
21. SHERR CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
22. NYLANDER K, STENLING R, GUSTAFSSON H, ZACKRISSON B, ROOS G. p53 expression and cell proliferation in squamous cell carcinoma of the head and neck. Cancer 1995; 75: 87-93.
23. KUSAMA K, OKUTSU S, TAKEDA A, et al. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996; 178: 415-21.
24. SHIN DM, KIM J, RO JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 321-6.
25. ICHIKAWA M, ISHII K, NAKAJIMA T, MOGI K. The overexpression of p53 and proliferative activity in precancerous and cancerous lesions of oral squamous epithelium. J Exp Clin Cancer Res 1997; 16: 141-6.
26. GIROD SC, KRUEGER G, PAPE HD. p53 and Ki-67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int J Oral Maxillofac Surg 1993; 22: 285-8.
27. NYLANDER K, SCHILDT EB, ERIKSSON M, ROOS G. PCNA, Ki-67, p53, bcl-2 and prognosis in intraoral squamous cell carcinoma of the head and neck. Anal Cell Pathol 1997; 14: 101-10.
28. ZOELLER J, FLENTJE M, SINN P, BORN IA. Evaluation of AgNOR and Ki-67 antigen as cell kinetic parameters in oral dysplasias and carcinomas. Anal Cell Pathol 1994; 7:77-88.
29. Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998; 152: 585-90.
30. MAO EJ, SCHWARTZ SM, DALING JR, ODA D, TICKMAN L, BECKMANN AM. Human papilloma viruses and p53 mutations in normal, pre-malignant and malignant oral epithelia. Int J Cancer 1996; 69: 152-8.
31. SHERR CJ, ROBERTS JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Der 1995; 9: 1149-63.
32. REED SI, BAILLY E, DULIC V, HENGST L, RESNITZKY D, SLINGERLAND J. G1 control in mammalian cells. J Cell Sci Suppl 1994; 18: 69-73.
33. YANG G, ZHANG Z, LIAO J, et al. Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int J Cancer 1997; 72: 746-51.
34. SANO T, OYAMA T, KASHIWABARA K, FUKUDA T, NAKAJIMA T. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998; 48: 580-5.
35. REED AL, CALIFANO J, CAIRNS P, et al. High frequency of p16(CDKN2/MTS-1/ INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3.
36. GONZALEZ MV, PELLO MF, LOPEZ-LARREA C, SUAREZ C, MENENDEZ MJ, COTO E. Deletion and methylation of the tumor suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997; 50: 509-12.
37. EL-NAGGAR AK, LAI S, CLAYMAN G. et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997; 151: 1767-74.
38. REGEZI JA, ZARBO RJ, REGEV E, PISANTY S, SILVERMAN S, GAZIT D. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 1995; 24: 18-22.
39. LOPEZ-AMADO M, GARCIA-CABALLERO T, LOZANO-RAMIREZ A, LABELLA-CABALLERO T. Human papillomavirus and p53 oncoprotein in verrucous carcinoma of the larynx. J Laryngol Otol 1996; 110: 742-7.
40. MEDINA JE, DICHTEL W, LUNA MA. Verrucous-squamous carcinomas of the oral cavity. A clinicopathologic study of 104 cases. Arch Otolaryngol 1984; 110: 437-40.
41. ADLER-STORTHZ K, NEWLAND JR, TESSIN BA, YEUDALL WA, SHILLITOE EJ. Human papillomavirus type 2 DNA in oral verrucous carcinoma. J Oral Pathol 1986; 15: 472-5.
42. BRANDSMA JL, STEINBERG BM, ABRAMSON AL, WINKLER B. Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. Cancer Res 1986; 46: 2185-8.
43. KASPERBAUER JL, O'HALLORAN GL, ESPY MJ, SMITH TF, LEWIS JE. Polymerase chain reaction (PCR) identification of human papillomavirus (HPV) DNA in verrucous carcinoma of the larynx. Laryngoscope 1993; 103: 416-20.
44. LUBBE J, KORMANN A, ADAMS V, et al. HPV-11-and HPV-16-associated oral verrucous carcinoma. Dermatology 1996; 192: 217-21.
45. HAWLEY-NELSON P, VOUSDEN KH, HUBBERT NL, LOWY DR, SCHILLER JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-10.
46. MUNGER K, PHELPS WC, BUBB V, HOWLEY PM, SCHLEGEL R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63: 4417-21.
47. WERNESS BA, LEVINE AJ, HOWLEY PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
48. DYSON N, HOWLEY PM, MONGER K, HARLOW E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
49. SAKAGUCHI M, FUJII Y, HIRABAYASHI H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996; 65: 442-5.
50. GULLEY ML, NICHOLLS JM, SCHNEIDER BG, AMIN MB, RO JY, GERADTS J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998; 152: 865-9.
51. KASHIWABARA K, OYAMA T, SANO T, FUKUDA T, NAKAJIMA T. Correlation between methylation status of the p16/ CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998; 79: 215-20.